A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis-Reference-Cited by-同舟云学术

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Published:2018-01-29 Issue:5 Volume:67 Page:1890-1902
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Kowdley Kris V.¹,Luketic Velimir²,Chapman Roger³,Hirschfield Gideon M.⁴,Poupon Raoul⁵,Schramm Christoph⁶,Vincent Catherine⁷,Rust Christian⁸,Parés Albert⁹,Mason Andrew¹⁰,Marschall Hanns-Ulrich¹¹,Shapiro David¹²,Adorini Luciano¹²,Sciacca Cathi¹²,Beecher-Jones Tessa¹²,Böhm Olaf¹³,Pencek Richard¹²,Jones David¹⁴,

Affiliation:

1. Liver Care Network; Swedish Medical Center; Seattle WA

2. Virginia Commonwealth University and McGuire Research Institute; McGuire DVAMC; Richmond VA

3. Department of Gastroenterology, John Radcliffe Hospital; Headington; Oxford UK

4. Centre for Liver Research and NIHR Biomedical Research Centre; University of Birmingham; Birmingham UK

5. Hôpital Saint-Antoine, AP-HdP; Paris France

6. 1st Department of Medicine; University Medical Center Hamburg-Eppendorf; Hamburg Germany

7. Liver Unit; Hôpital Saint-Luc; Montréal Canada

8. Department of Medicine 2, Grosshadern; University of Munich; Munich Germany

9. Liver Unit, Hospital Clinic, IDIBAPS, CIBERehd; University of Barcelona; Barcelona Spain

10. Division of Gastroenterology; University of Alberta; Edmonton Alberta Canada

11. Sahlgrenska Academy; Department of Molecular and Clinical Medicine, University of Gothenburg; Gothenburg Sweden

12. Intercept Pharmaceuticals Inc.; San Diego CA

13. FGK Clinical Research; Munich Germany

14. Institute of Cellular Medicine; Newcastle University; Newcastle-upon-Tyne UK

Funder

Intercept Pharmaceuticals, Inc.

Publisher

Wiley

Subject

Hepatology

Reference32 articles.

1. The immunobiology and pathophysiology of primary biliary cirrhosis;Hirschfield;Annu Rev Pathol,2013

2. Changing nomenclature for PBC: from “cirrhosis” to “cholangitis;Beuers;Hepatology,2015

3. EASL clinical practice guidelines: management of cholestatic liver diseases;European Association for the Study of the Liver;J Hepatol,2009

4. Primary biliary cirrhosis: AASLD practice guidelines;Lindor;Hepatology,2009

5. Predicting outcome in primary biliary cirrhosis;Lammers;Ann Hepatol,2014

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolomics and serum pharmacochemistry combined with network pharmacology uncover the potential effective ingredients and mechanisms of Yin-Chen-Si-Ni Decoction treating ANIT-induced cholestatic liver injury;Journal of Ethnopharmacology;2024-12

2. ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis;Journal of Controlled Release;2024-10

3. Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways;Toxicology and Applied Pharmacology;2024-09

4. S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV);Zeitschrift für Gastroenterologie;2024-09

5. Si-Ni-San ameliorates cholestatic liver injury by favoring P. goldsteinii colonization;Journal of Ethnopharmacology;2024-09